Abivax SA (ABVX) Stock Forecast: StockMap's 2-Week Call
ABVX stock forecast: StockMap's model makes no two-week call on Abivax SA after the Nov 19 close: its evidence is split, 7 reasons for and 8 against. Right in 4 of 6 two-week windows on ABVX since Aug 21; by chance, a call on the same dates was right 58% of the time.
Abivax SA last closed at $80.65, -3.79% on the session.
Against the IVW growth benchmark the position is -1.46% over the forecast window.
Abivax SA's market cap is $6.44B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 8 (too close to call).
Where ABVX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
38 daily calls for ABVX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Abivax SA in the 12th percentile on return on equity, where 100 is best.
Abivax SA is classified under Health Care / Pharmaceuticals.
StockMap tracks Abivax SA as the 23rd largest of the 153 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.
Across that group the current two-week reads are 80 Moderate Underperform, 44 Neutral and 29 Strong Underperform.
On that composite Abivax SA ranks 7th of 153 in the group, against a group median of -0.36.